S-1/A: Caring Brands Files Amendment No. 1 to Form S-1 for IPO and Resale of Common Stock

Caring Brands, Inc. files an amended registration statement for its initial public offering of 750,000 shares and the potential resale of 6,220,000 shares by selling stockholders.

Summary

• Caring Brands, Inc. has filed Amendment No. 1 to its Form S-1 registration statement with the SEC.
• The registration statement covers both an initial public offering (IPO) of up to 750,000 shares of common stock and the potential resale of up to 6,220,000 shares by selling stockholders.
• The resale shares include shares issued in private placements, shares issuable upon exercise of warrants, and shares to be distributed to Safety Shot, Inc.'s stockholders.
• The company anticipates an initial public offering price of $4.00 per share.
• Caring Brands has applied to list its common stock on the NASDAQ Capital Markets under the symbol CABR, but there is no assurance that the application will be approved.
• The completion of the offering is contingent on NASDAQ approval.
• The company is an emerging growth company and may elect to comply with certain reduced public company reporting requirements.
• The company intends to use the net proceeds from the IPO for general and working capital purposes, including research and development and debt repayment.
• Safety Shot will distribute 2,000,000 shares of Caring Brands' common stock to its stockholders and certain warrant holders.
• The distribution is expected to be taxable to both Safety Shot and its stockholders.
• The company's products include Photocil, Hair Enzyme Booster (JW-700), CB-101 treatment for Atopic Dermatitis (Eczema), and NoStingz.
• The company has entered into a license agreement with NOVODX Corporation for the Ebola Rapid Test.
• The company has a license agreement with Cosmofix and San Pellegrino cosmetics to market and manufacture the Hair Enzyme Booster (JW-700) and Photocil for the Indian market and 31 other companies in Africa and Far East.
• The company has a license agreement with Taisho Pharmaceutical Co., Ltd. for the Hair Enzyme Booster (JW-700) in Japan.
• The company has four full-time employees.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the company's diverse product pipeline and license agreements, there are also significant risks and challenges, including a limited operating history, going concern doubts, and potential conflicts of interest. The financial results for the year ended December 31, 2024, are worse than the previous year, indicating a negative trend.

Positives

• The company has a diverse product pipeline including hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and womens sexual wellness products.
• The company has a license agreement with Cosmofix and San Pellegrino cosmetics to market and manufacture the Hair Enzyme Booster (JW-700) and Photocil for the Indian market and 31 other companies in Africa and Far East.
• The company has a license agreement with Taisho Pharmaceutical Co., Ltd. for the Hair Enzyme Booster (JW-700) in Japan.
• The company has entered into a license agreement with NOVODX Corporation for the Ebola Rapid Test.

Negatives

• The company has a limited operating history.
• The company may not have adequate capital to fund its business.
• The company may not be able to successfully compete against companies with substantially greater resources.
• The sale of the company's products involves product liability and related risks that could expose the company to significant insurance and loss expenses.
• The company's financial situation creates doubt whether the company will continue as a going concern.

Risks

• The company may be unable to achieve some or all of the benefits that it expects to achieve from the separation from Safety Shot.
• The company may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as a publicly traded company, and the company may experience increased costs after the separation.
• The distribution, together with certain related transactions, does not qualify as a transaction that is generally tax-free for U.S. federal income tax purposes, Safety Shot and its stockholders could be subject to significant tax liabilities.
• Some of the company's directors and executive officers own Safety Shot common stock or options to acquire Safety Shot common stock and hold positions with Safety Shot, which could cause conflicts of interest, or the appearance of conflicts of interest, that result in the company not acting on opportunities it otherwise may have.
• The company has a limited operating history, which makes it difficult to accurately evaluate the company's business prospects.
• The company may not have adequate capital to fund its business.
• The company may not be able to successfully compete against companies with substantially greater resources.
• The sale of the company's products involves product liability and related risks that could expose the company to significant insurance and loss expenses.
• Raising additional capital may cause dilution to the company's existing stockholders, restrict the company's operations or require the company to relinquish rights to the company's technologies or other assets.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• If the company is not able to adequately protect its intellectual property, then the company may not be able to compete effectively, and the company may not be profitable.
• The company is an emerging growth company and the company cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make the company's common stock less attractive to investors.
• The company's common stock may become subject to the SECs penny stock rules and accordingly, broker-dealers may experience difficulty in completing customer transactions and trading activity in the company's securities may be adversely affected.
• Investing in the company is highly speculative and could result in the entire loss of your investment.

Future Outlook

The company plans to relaunch Photocil in the United States in 2025 and is exploring manufacturing and marketing options. The company also plans to expand its sales and marketing team, which it expects will accelerate product commercialization efforts and drive increased market penetration.

Industry Context

The company operates in the competitive wellness consumer products industry, facing competition from larger companies with greater resources. The company's products are differentiated through a unique mechanism of action that offers clinical benefits not provided by traditional products. The company plans to leverage targeted marketing strategies and education to build brand trust and establish itself as a competitive alternative to existing brands.

Comparison to Industry Standards

• The global psoriasis treatment market was worth ~$34 billion globally in the 12 months ending June 2023, with the US accounting for approximately 78% of total sales and growing at a compound annual growth rate of approximately 18% according to Nature Reviews Drug Discovery (2024).
• The global vitiligo treatment market was valued at ~$538.90 million in 2024 and is projected to grow at a CAGR of 4.60% from 2025 to 2034, reaching ~$807.70 million by 2034 according to Expert Market Research (2024).
• The minoxidil market was valued at $1.5 billion in 2022 and is expected to grow to $2.5 billion by 2032.

Related Party Transactions

• Nancy Torres is a Director of the Company and the CEO of NOVODX Corporation, a Delaware corporation (NOVODX).
• In May 2024, NOVODX participated in the Companys private placement by acquiring 500,000 shares of the Companys common stock for $500,000 cash, representing an approximate 4% equity ownership in the Company.
• In June, 2024, the Company invested $500,000 in NOVODXs private placement to purchase 25,134 shares of NOVODX common stock representing less than 1% of NOVODX.
• On June 20, 2024, the Company entered into a Research Collaboration and Non-Exclusive License Agreement, as amended and restated on July 22, 2024 (the License Agreement) with NOVODX.

Stakeholder Impact

• The distribution of shares to Safety Shot stockholders will be a taxable event.
• The company's financial situation creates doubt whether the company will continue as a going concern, which could impact investors.
• The company's success depends on its ability to create and expand its brand awareness, which will impact its ability to attract customers and distributors.
• The company's ability to comply with regulations for cosmetic and OTC products from various U.S. and international governmental agencies will impact its ability to market its products.

Next Steps

• The company plans to relaunch Photocil in the United States in 2025.
• The company plans to expand its sales and marketing team.
• The company intends to complete the reformulation and initiate the stability testing of NoStingz by the second quarter of 2025.
• The company intends to complete the reformulation and stability testing of CB-101 by the end of the third quarter of 2025.
• The company plans to initiate the production run and clinical testing for CB-101 by the fourth quarter of 2025.

Key Dates

Keywords

IPO, initial public offering, resale, common stock, Caring Brands, Safety Shot, Photocil, Hair Enzyme Booster, CB-101, NoStingz, NOVODX, Cosmofix, San Pellegrino, Taisho, emerging growth company, NASDAQ